SF500

SF500 is a biotechnology acceleration program and impact investment firm based in Rosario, Argentina, established in 2022. The company focuses on transforming scientific projects into successful biotech startups by identifying outstanding scientific ideas and assembling strong teams with both scientific and business expertise. SF500 runs a rigorous 12-week program twice a year for 15 selected candidates, emphasizing science, team dynamics, and product development. Participants in the program may receive a pre-seed investment of $250,000. The firm offers extensive support through its dedicated portfolio management team, which assists startups from the investment phase onward, providing services such as legal assistance, intellectual property support, lab facilities, and connections to a network of international investors. SF500 aims to invest in areas such as carbon neutrality, biomaterials, regenerative agriculture, functional foods, diagnostics, health, and wellness.

Francisco Buchara

Co-Founder, Managing Partner and CEO

21 past transactions

Pill.AR

Pre Seed Round in 2024
Pill.AR is a biotechnology company focused on developing personalized medication solutions to enhance the quality of life for individuals. By leveraging advanced pharmaceutical technology, the company aims to tailor treatments to meet the unique needs of patients. Currently operating in stealth mode, Pill.AR is positioned to innovate within the pharmaceutical landscape, seeking to improve health outcomes through customized therapeutic approaches.

NotFossil

Pre Seed Round in 2024
NotFossil is a biotechnology company that offers hydrocarbon bioremediation services for wastewater treatment.

Gameet

Pre Seed Round in 2024
Gameet is a biotechnology startup that emulates the natural processes of sperm selection and growth in a device printed with 3D technology.

Tintte

Pre Seed Round in 2024
Tintte is an innovative company focused on transforming the textile dyeing industry through biotechnology. By utilizing specifically selected bacteria, Tintte develops bio dyes and bio compounds that eliminate the need for harmful chemicals and toxins, significantly reducing environmental impact. The company's advanced biotechnological process allows for the sustainable, efficient, and scalable production, deposition, and fixation of pigments on textiles. This approach not only minimizes the consumption of drinking water and energy but also aims to drastically reduce pollution associated with traditional dyeing methods, positioning Tintte as a leader in sustainable textile solutions.

MesencHyal-T

Pre Seed Round in 2024
MesencHyal-T is a biotechnology company that develops cellular medical therapies for the treatment of tissue regeneration.

BioMetallum

Pre Seed Round in 2023
BioMetallum is a biomining company specializing in sustainable metal extraction. It designs and develops solutions, primarily focused on lithium, using microorganisms to enhance efficiency and minimize environmental impact. The company's services promote a circular economy, aiming to enable a healthier, more sustainable society.

Inmet

Pre Seed Round in 2023
Inmet S.A. is a biotechnology company that specializes in optimizing microorganisms to transform agro-industrial residues into high-value compounds. The company employs a multidisciplinary approach in synthetic biology to design and genetically optimize these microorganisms for various industrial applications. By focusing on environmentally friendly technologies, Inmet aims to convert waste materials into sustainable and biodegradable products, allowing clients to replace traditional chemical products with safer, more eco-friendly alternatives. This commitment to minimizing environmental impact while utilizing low-cost raw materials positions Inmet as an innovator in the field of biotransformation and sustainable practices.

Trebe Biotech

Pre Seed Round in 2023
Trebe Biotech is a biotechnology startup focused on the production of high-quality and complex recombinant proteins. The company offers an innovative, high-throughput platform that caters to the veterinary and diagnostic medicine sectors. By providing customized services, Trebe Biotech enables strategic partners to access a flexible and efficient solution for protein production, thereby facilitating advancements in their respective fields.

Mycorium Biotech

Pre Seed Round in 2023
Mycorium Biotech is an innovative company focused on upcycling waste to produce bioleather, a sustainable alternative to synthetic leather. By utilizing a fungal biotech platform, Mycorium Biotech efficiently converts waste materials into biodegradable leather, addressing the pressing sustainability issues within the fashion industry, which is one of the most polluting sectors globally. The company's mission aligns with the principles of responsible production and consumption, promoting eco-friendly materials that support the shift away from plastics. Mycorium Biotech aims to provide the fashion industry with organic bioleather, enabling consumers to make environmentally conscious choices in their garment selections.

Exomas

Pre Seed Round in 2023
Exomas develops disruptive solutions based on exosomes derived from neural stem cells for the preventive or regenerative treatment of nervous tissue affected by neurodegenerative diseases. These exosomes have the ability to induce the proliferation of neural stem cells and their differentiation into functional neurons, thus exerting a neuroregenerative effect on the affected tissue.

Unibaio

Pre Seed Round in 2023
Unibaio specializes in biodegradable nano-encapsulation technology designed to optimize the delivery of agrochemicals, thereby reducing the need for harmful chemicals in pesticide formulations. The company's innovative particles enable pesticide manufacturers to comply with stringent environmental regulations while maintaining effective chemical use. Unibaio's technology enhances the uptake of fertilizers and pesticides, minimizing runoff and lowering application doses, which ultimately decreases costs for farmers. By utilizing natural compounds such as shrimp waste and clay, Unibaio adheres to a circular model in producing its micro-nanocapsules. This approach supports the development of both traditional and organic agricultural products, improving yield and competitiveness in the sector while promoting the health and well-being of crops.

MultiplAI Health

Seed Round in 2023
MultiplAI Health is a biotechnology company that focuses on enhancing disease detection through advanced blood screening tests. Utilizing RNA sequencing and artificial intelligence, the company analyzes a wide array of biomarkers in whole blood samples to identify complex diseases, including cardiovascular disorders and cancers. This innovative approach allows for universal remote screening, enabling both preventative assessments and post-treatment monitoring. The simplicity of a liquid biopsy means that tests can be conducted anywhere with just a blood sample, making them accessible and cost-effective compared to traditional diagnostic methods. By facilitating earlier detection of diseases in asymptomatic individuals, MultiplAI Health aims to improve patient prognoses and treatment strategies through more accurate diagnostic insights.

TELL Toolkit

Pre Seed Round in 2023
TELL is on a mission to revolutionize the fight against neurodegenerative diseases like Alzheimer's, Parkinson's, and frontotemporal dementia. The company's innovative approach to brain health combines automated speech and language analysis with cutting-edge AI technology to detect early markers and provide reliable data to get to diagnoses. The company's HIPAA-compliant SaaS solution is designed to address the challenges of early detection, specificity, cost, access, and reliability. By offering a unified, user-friendly, and scalable tool for discovering and implementing novel markers, we're bringing hope to patients, caregivers, and healthcare professionals across the globe. So, whether you're a patient, physician, biotech company, health insurance provider, or government agency, TELL is here to help you make better decisions and improve brain health for all.

EirĂș

Pre Seed Round in 2023
EirĂș is a biotechnology company that offers a biodiversity MRV system for conservation related decision making.

M4Life

Pre Seed Round in 2023
M4Life is a biotechnology company specializing in soil restoration and crop enhancement. It has developed a proprietary method using bio-trained microbes, which are introduced into soil via seeds, to boost plant resilience and productivity. This non-GMO approach helps crops thrive under harsh conditions like drought, high temperatures, and salinity, increasing yields by 44% and improving nutritional content. Additionally, it aids in carbon capture by restoring degraded soils and halting deforestation.

Eureka Nanobioengineering

Pre Seed Round in 2023
Eureka Nanobioengineering is a developer of a proprietary platform focused on the creation of advanced nanobiodevices and functional nanobiomaterials. The company's technology emphasizes protein engineering to manipulate the self-assembly mechanisms of various viral proteins, facilitating the oligomerization of proteins. Eureka's platform supports a wide range of applications, including immune system programming, allergen immunotherapy, vaccine development, antibody and small molecule conjugation, as well as personalized medicine and therapeutics. By providing innovative solutions across multiple scientific and technological domains, Eureka Nanobioengineering aims to advance the field of nanobiotechnology and enhance diagnostic tools.

Limay Biosciences

Seed Round in 2022
Limay Biosciences is a biotechnology company focused on creating innovative molecular testing solutions for food quality and health assessment. The company has developed a platform that offers simple, precise, and cost-effective tools for on-site testing of DNA, RNA, and protein targets. By providing automated testing services, Limay Biosciences enables businesses to make informed decisions quickly and efficiently, enhancing their ability to monitor and ensure quality in various applications. The emphasis on accessibility and affordability positions Limay Biosciences as a key player in the advancement of molecular diagnostics.

BiotaLife Skin

Pre Seed Round in 2022
BiotaLife Skin is a biotechnology company that offerssSkin microbiome detection and treatment services.

Oncoliq

Pre Seed Round in 2022
Oncoliq is a startup focused on developing an innovative screening method for early cancer detection through liquid biopsy, which utilizes a small blood sample. The company is particularly concentrated on the early detection of breast and prostate cancer, while also exploring the potential for identifying additional cancer types. By employing a simple blood test that detects microRNAs, Oncoliq aims to create a comprehensive diagnostic tool capable of facilitating the early detection of up to 50 different types of cancer. This approach is designed to enable patients to identify cancer at an earlier stage, potentially improving treatment outcomes.

BEAM CropTech

Seed Round in 2022
BEAM CropTech is a biotechnology company specializing in genetic engineering to optimize crop growth and increase yield. It focuses on enhancing photosynthesis through advanced genetic technologies, aiming to improve global food security. The company's process involves identifying and characterizing genes, validating discoveries in prototype plants, protecting intellectual property, partnering with seed companies, and transferring knowledge to create social, environmental, and economic value. This enables clients to maintain yields despite future climate challenges.

Dharma Bioscience

Pre Seed Round in 2022
Dharma Bioscience is a biotechnology company specializing in the development of an injectable treatment using modified microRNAs to stimulate cartilage regeneration in osteoarthritis patients. This innovative therapy offers a simple administration method for healthcare providers, reducing the need for invasive joint replacement surgeries. By providing a non-invasive alternative, this treatment minimizes recovery time, associated costs, and presents a safer, more accessible option for patients managing their condition.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.